Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.54
MNKD's Cash to Debt is ranked lower than
85% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. MNKD: 0.54 )
Ranked among companies with meaningful Cash to Debt only.
MNKD' s 10-Year Cash to Debt Range
Min: 0  Med: 0.54 Max: No Debt
Current: 0.54
F-Score: 4
Z-Score: -8.82
M-Score: -3.82
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -55.23
MNKD's ROA (%) is ranked lower than
73% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. MNKD: -55.23 )
Ranked among companies with meaningful ROA (%) only.
MNKD' s 10-Year ROA (%) Range
Min: -393.74  Med: -66.24 Max: -52.52
Current: -55.23
-393.74
-52.52
ROC (Joel Greenblatt) (%) -80.61
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. MNKD: -80.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -570.67  Med: -96.53 Max: -70.3
Current: -80.61
-570.67
-70.3
EBITDA Growth (3Y)(%) -28.90
MNKD's EBITDA Growth (3Y)(%) is ranked lower than
79% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. MNKD: -28.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MNKD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43  Med: -25.45 Max: 10.9
Current: -28.9
-43
10.9
EPS Growth (3Y)(%) -27.20
MNKD's EPS Growth (3Y)(%) is ranked lower than
76% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. MNKD: -27.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MNKD' s 10-Year EPS Growth (3Y)(%) Range
Min: -42.9  Med: -23.00 Max: 7.6
Current: -27.2
-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MNKD Guru Trades in Q2 2014

Jim Simons 1,769,800 sh (New)
Paul Tudor Jones 29,250 sh (New)
Murray Stahl 73,850 sh (-45.09%)
» More
Q3 2014

MNKD Guru Trades in Q3 2014

Murray Stahl 137,271 sh (+85.88%)
Jim Simons Sold Out
Paul Tudor Jones 11,246 sh (-61.55%)
» More
Q4 2014

MNKD Guru Trades in Q4 2014

Jim Simons 893,852 sh (New)
Murray Stahl 158,109 sh (+15.18%)
Paul Tudor Jones Sold Out
» More
Q1 2015

MNKD Guru Trades in Q1 2015

Murray Stahl 162,457 sh (+2.75%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 384.62
MNKD's Forward P/E is ranked lower than
95% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. MNKD: 384.62 )
Ranked among companies with meaningful Forward P/E only.
N/A
PFCF 113.80
MNKD's PFCF is ranked lower than
74% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 33.86 vs. MNKD: 113.80 )
Ranked among companies with meaningful PFCF only.
MNKD' s 10-Year PFCF Range
Min: 0  Med: 0.00 Max: 144.6
Current: 113.8
0
144.6
POCF 51.73
MNKD's POCF is ranked lower than
65% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 31.61 vs. MNKD: 51.73 )
Ranked among companies with meaningful POCF only.
MNKD' s 10-Year POCF Range
Min: 0  Med: 0.00 Max: 60.9
Current: 51.73
0
60.9
Current Ratio 0.42
MNKD's Current Ratio is ranked lower than
94% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. MNKD: 0.42 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s 10-Year Current Ratio Range
Min: 0.12  Med: 1.74 Max: 12.24
Current: 0.42
0.12
12.24
Quick Ratio 0.37
MNKD's Quick Ratio is ranked lower than
94% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. MNKD: 0.37 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s 10-Year Quick Ratio Range
Min: 0.12  Med: 1.74 Max: 12.24
Current: 0.37
0.12
12.24

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -6.23
MNKD's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. MNKD: -6.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MNKD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -11.3  Med: 0.00 Max: 0
Current: -6.23
-11.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NNF1.Germany,
MannKind Corp a development stage biopharmaceutical company, was incorporated in the state of Delaware on February 14, 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Its other product MKC253, MKC253 is a Technosphere formulation of GLP-1. Results from a phase 1 trial supported the hypothesis that inhalation of MKC253 may be able to simulate the incretin effect that is lost in patients with type 2 diabetes. Products manufactured in the United States and marketed outside the United States are subject to certain FDA regulations, as well as regulation by the country in which the products are to be sold.
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
own Mar 02 2015 
investment Feb 28 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
Portfolio 1 Jan 03 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 

More From Other Websites
The 6 Most Heavily Shorted Nasdaq Stocks in June Jun 25 2015
Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail! Jun 19 2015
MannKind's 3 Can't-Miss Quotes at Goldman Sachs Jun 17 2015
MannKind Corporation Sinks: CFO Says 'We're Not There Yet' With Afrezza Jun 10 2015
5 Stocks a Raging Rally Could Not Save Jun 10 2015
The 6 Most Shorted Nasdaq Stocks in May Jun 10 2015
Why MannKind Could Be an Endless Tug-of-War Stock Jun 09 2015
Diabetes Docs Wary of MannKind's Afrezza Insulin, Analyst Survey Finds Jun 09 2015
Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala Jun 09 2015
Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala Jun 09 2015
3 Big Stocks on Traders' Radars -- and What to Do With Them Jun 08 2015
MannKind (MNKD) Worth a Look: Stock Adds 5.7% in Session - Tale of the Tape Jun 08 2015
Jefferies: MannKind's Consumer Ads For Afrezza May Increase Awareness Jun 04 2015
MannKind Continues To Be Friendly To Investors Jun 03 2015
MannKind's inhaled insulin drug proves hard for diabetics to get Jun 03 2015
Is This Diabetes Stock a Better Bet Than MannKind? May 27 2015
MannKind to Present at Upcoming Conferences May 27 2015
MannKind to Present at Upcoming Conferences May 27 2015
MANNKIND CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK